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Two thirds of ventilated COVID-19 patients require vaso-
pressor support [1]. Recommended vasopressors include
norepinephrine and vasopressin. Recently, based on a ran-
domized trial [2], angiotensin II (ANGII) was FDA- and
EMA-approved for catecholamine-resistant vasodilatory
shock. ANGII use as primary vasopressor for vasodilatory
shock has never been reported, let alone for COVID-19-
associated vasodilatory shock. ANGII may be logical in this
setting. It specifically assists patients recently exposed to
angiotensin-converting enzyme inhibitors [2, 3] and increases
the internalization and downregulation of angiotensin-
converting enzyme 2 [4], the receptor for COVID-19. Its use
may also inform the debate about the risks and benefits of
angiotensin receptor blockers in COVID-19-infected patients
[5]. In this pilot compassionate-use case series, we used
ANGII either as primary or rescue vasopressor in ventilated
patients with COVID-19-associated vasodilatory shock and
assessed the course of key physiological variables during the
first 48 h of treatment.
We studied a cohort of consecutive ventilated patients in
COVID-19-dedicated ICUs at San Raffaele Scientific Insti-
tute, Milan, Italy. Patients had vasodilatory shock and
COVID-19-related infection (positive viral RNA biospeci-
men and typical clinical and radiological features). The Eth-
ics Committee approved compassionate use of the drug.
All cases received commercial ANGII (Giapreza®, La Jolla
San Diego, CA) as continuous infusion started at 20 ng/kg/
min and titrated to a MAP target > 65mmHg. We collected
key data before and during 48 h of angiotensin II infusion.
Over 6 days (March 12 to March 18, 2020) we treated
16 patients, 10 with ANGII as first-line agent, five as
second-line agent (Table 1), and one patient with
unobtainable data. ANGII dose was relatively constant.
MAP and urine output remained stable; lactate and cre-
atinine increased and C-reactive protein decreased
(Table 1). However, the SpO2/FiO2 ratio increased sig-
nificantly with a decrease in FiO2 and PEEP (Fig. 1). At
latest follow-up (1 week), 14 patients were alive.
In ventilated patients with COVID-19-associated vaso-
dilatory shock, we assessed the initial physiological
changes associated with ANGII infusion as primary or res-
cue vasopressor. Overall, the administration of ANGII was
associated with achievement and maintenance of target
MAP, an increase on SpO2/FiO2 ratio, and a decrease in
FiO2. These oxygenation improvements were significant.
This represents the first experience with ANGII in
COVID-19-associated vasodilatory shock and with
ANGII as primary vasopressor in humans. The findings
are consistent with those of a previous trial and subse-
quent subgroup [2] and ANG I/II ratio-related analyses
[3]. They suggest the absence of early physiologically
harm and improved oxygenation with ANG II.
The key limitations of this study are obvious. It is
single-center, small, observational in nature; lacks a con-
trol population; and is open-label. However, in this pan-
demic setting, the ethics of ensuring compassionate drug
use to all patients were considered a priority. Moreover,
before considering controlled trials, evidence of some
physiological safety was considered important. Finally,
under the extraordinary pressures of the most dramatic
health disaster in Italy’s history in a century, this study
was the best possible under the circumstances.
In conclusion, we provide the first observational co-
hort study of ANGII infusion in ventilated patients with
COVID-19-associated vasodilatory shock. Our findings
provide preliminary evidence to assist clinicians in their
choice of vasopressors and justify and help design future
controlled studies.
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Table 1 Baseline characteristics and physiological changes in treated patients
Baseline
(n = 15)
After 24 h
(n = 15)
After 48 h
(n = 15)
Age, years 64 (54–69) – –
Male gender 11 (73.3) – –
Angiotensin II as first-line agent 10 (66.7) – –
Angiotensin II dose, ng/kg/min 20.0 (5.0–20.0) 20.0 (8.4–20.8) 20.0 (8.1–20.8)
Support and drugs
High dose catecholamine (> 0.25 μg/kg/min) 1 (6.7) – –
Receiving catecholamine > 12 h 2 (13.3) – –
Prone positioning 5 (41.7) 11 (78.6) 11 (78.6)
Use of tocilizumab 5 (35.7) – –
Norepinephrine dose, μg/kg/min 0.10 (0.10–0.20) 0.02 (0.00–0.09) 0.01 (0.00–0.14)
Hours using before 8.5 (1.8–15.8) – –
Vital signs at start
Systolic arterial pressure, mmHg 110 (95–115) 110 (105–129) 120 (115–120)
Diastolic arterial pressure, mmHg 60 (52–64) 60 (56–64) 70 (59–70)
Mean arterial pressure, mmHg 71 (65–79) 77 (76–80) 85 (80–87)
Heart rate, bpm 82 (70–92) 72 (68–83) 71 (66–76)
Atrial fibrillation 1 (7.1) – –
Cumulative urine output, mL 237.5 (71.2–365.0) 620.0 (385.0–750.0) 727.0 (470.0–1050.0)
Oliguria 3 (30.0) – –
Ventilatory support
FiO2 0.70 (0.61–0.70) 0.50 (0.40–0.60) 0.40 (0.36–0.54)
PEEP, cmH2O 14 (12–15) 12 (10–12) 11 (10–14)
SpO2, % 97 (94–99) 98 (96–98) 97 (91–98)
PaO2/FiO2 121.4 (98.1–218.1) 195.2 (148.3–245.0) 200.0 (168.0–248.5)
SpO2/FiO2 140.7 (132.5–150.6) 191.5 (118.4–258.0) 193.8 (142.2–235.9)
Laboratory tests at start
Lactate, mmol/L 1.49 (1.36–1.56) 1.72 (1.58–2.00) 1.83 (1.53–2.15)
Creatinine, mg/dL 1.00 (0.85–1.68) 1.69 (1.16–2.38) 1.69 (1.06–2.43)
C-reactive protein, mg/dL 232.3 (165.4–269.2) 202.0 (148.4–231.1) 115.0 (95.0–190.4)
White blood cell count, × 1000 cells/mm3 11.9 (7.7–13.2) 10.1 (6.2–12.4) 9.2 (7.2–14.2)
Lymphocyte count, × 1000 cells/mm3 5.30 (3.05–16.222) 7.90 (3.70–12.85) 8.30 (5.20–13.50)
Data are median (quartile 25% to quartile 75%) or N (%)
PEEP positive end-expiratory pressure
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Fig. 1 Changes in oxygenation parameters in the first 48 h of angiotensin II infusion. Data are median and quartile 25% to quartile 75%. The
changes in the parameters over time were assessed with a mixed–effect quantile model based on the asymmetric Laplace distribution (τ = 0.50, a
median regression), taking into account repeated measurements and considering the time of measurements (as a continuous variable) as fixed
effect. The p value in the graphs represents the changes over this time. In all models, only values at and after the start of the infusion drug were
taken into account, and the values before the start were used only for graphic purpose. All results were confirmed after bootstrapping with
10,000 replications. All analyses were conducted in R (R Foundation), version 3.6.3
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